Zydus Wellness shares jump 19% as MoFSL targets ₹575

Stock spikes on heavy volumes, nears record high

Zydus Wellness shares surged as much as 19% to ₹528.10 on the BSE during Monday’s intra-day trade, supported by heavy volumes. The move took the stock close to its record high of ₹530.55, which was touched on September 19, 2025. By 01:49 PM, the stock was still up 15% at ₹511.40, while the BSE Sensex was up 0.62% at the same time. The sharp move coincided with renewed focus on expected volume-led growth in the March 2026 quarter and brokerage commentary around valuation. In another session referenced in the data, the stock hit an intraday high of ₹483.40 and later closed at ₹465.50 after paring gains.

What investors are tracking: results, acquisition impact, dividends

The near-term narrative in the stock is tied to two clear triggers mentioned by analysts and market participants. First is the upcoming results trajectory and whether growth remains volume-led in the March 2026 quarter. Second is the dividend decision, which analysts flagged as a factor that could support shareholder value alongside steady expansion. Separately, ComfortClick, acquired in September 2025, has become a key factor in consolidated performance and margin optics. The company’s portfolio brands mentioned by analysts include Sugar Free, Glucon-D and Nutralite, which were described as potentially better insulated versus peers.

Q3FY26 numbers that stood out

For the October to December 2025 quarter (Q3FY26), the company reported sharp year-on-year growth in key operating lines. Consolidated net sales rose 113.7% YoY to ₹963.3 crore. EBITDA increased 312.2% YoY to ₹61.0 crore, and the update notes that this includes the post-acquisition performance of the newly acquired business. These numbers have become an anchor for expectations going into the next quarter, especially as the market tries to separate organic momentum from acquisition-led expansion.

Motilal Oswal initiates coverage with a Buy and ₹575 target

Motilal Oswal Financial Services initiated coverage on Zydus Wellness with a ‘Buy’ rating and a target price of ₹575 per share. In its note, the brokerage said it expects 8% organic business revenue growth in the March 2026 quarter led by volumes. It also highlighted that the acquisition of ComfortClick in September 2025 drove consolidated revenue growth. The brokerage expects “Max protein” to sustain strong double-digit growth momentum, and it also pointed to broader consumer sector observations such as rural demand remaining resilient and urban demand showing improvement.

Margin commentary: ComfortClick and FY28 assumptions

Motilal Oswal’s note explicitly links gross profit margin improvement to ComfortClick, described as the company’s UK subsidiary operating with a higher gross profit margin of 82%. On medium-term profitability, the brokerage said it models organic EBITDA margin of nearly 16% in FY28, while the company aims to achieve around 17%. It flagged an “upside risk” to its operating margin assumption for the organic business based on this gap. These assumptions are central to how the brokerage frames valuation and compares Zydus Wellness with other consumer peers.

Valuation framework and peer comparison used by the brokerage

Motilal Oswal stated the stock trades at 22x P/E and 16x EV/EBITDA on FY28E estimates, and that it is at a 30%-35% discount to other FMCG peers. The brokerage used a Sum of the Parts (SoTP) framework, valuing the India business at 27x EV/EBITDA FY28E and the international business (Comfort Click) at 15x EV/EBITDA FY28E. This led to an implied consolidated valuation of 22x EV/EBITDA and 30x P/E at FY28E, supporting the ₹575 target price.

Analyst fair value and price target revisions show a wide range

Alongside the brokerage initiation, the dataset includes multiple analyst fair value revisions for Zydus Wellness over time. Analysts were described as keeping fair value broadly unchanged around ₹544 per share with minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. Another update said the fair value estimate was lifted to ₹544.29 from ₹525.71 due to an updated future P/E assumption, with revenue growth, profit margins and the discount rate largely unchanged. In contrast, there was also a cut from ₹524.70 to ₹515.95, followed by an earlier move that adjusted fair value to ₹525.71 from ₹515.95 with a slightly higher future P/E of about 39.95x.

Key numbers snapshot

Timeline of cited analyst fair value and target changes

Growth expectations and risks highlighted

The dataset includes a forecast that earnings are expected to grow 32.27% per year. Motilal Oswal also referenced multi-year estimates, including 14% organic EBITDA CAGR and 36% consolidated EBITDA CAGR during FY25-28, and separately cited estimates of about 30% revenue CAGR and 35% EBITDA CAGR over FY25-28. It also listed key downside risks: dependence on seasonality, input cost volatility, underperformance in the HFD category, and increasing competitive intensity. Promoter holding was cited at 70% in the brokerage commentary.

Market impact: what moved the stock and what to monitor

The immediate market impact came through sharp price moves and heightened attention to quarterly growth cues. Traders appeared to respond to the combination of strong reported Q3FY26 growth, acquisition-led consolidation benefits, and the initiation of coverage with a ₹575 target. Attention is also on margins, particularly after the note that ComfortClick operates at an 82% gross profit margin, which can influence consolidated profitability trends. Separately, analyst fair value revisions show that small shifts in future P/E assumptions can materially change implied valuations, even when revenue growth and discount rate assumptions are described as broadly unchanged.

Conclusion

Zydus Wellness’ stock action has been driven by a mix of near-record price levels, strong YoY growth in Q3FY26, and fresh brokerage coverage pointing to volume-led organic growth in the March 2026 quarter. The next set of results and the dividend decision remain key near-term checkpoints cited by analysts, alongside updates on how ComfortClick influences consolidated margins and growth.